Drug Type Small molecule drug |
Synonyms KMO inhibitor(Kynos Therapeutics), Kynurenine 3-monooxygenase inhibitor(Kynos Therapeutics), KNS 366 |
Target |
Mechanism KMO inhibitors(kynurenine 3-monooxygenase inhibitors) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Start Date10 Jan 2023 |
Sponsor / Collaborator ![]() |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | Renal transplant rejection Kynurenine 3-monooxygenase (KMO) | indoleamine 2,3-dioxygenase (IDO) | - | cqfxctknrl(rbnarjkldj) = The addition of 3HK completely restored E-cadherin and TJP1 expression uhchhhynjc (ztzypocagh ) View more | Positive | 05 Nov 2019 | ||
Not Applicable | - | fyfoypcmam(aoachykigy) = 3HK inhibited proliferation of active Tcells and promoted Tcell injury and death. The same and higher concentrations of 3HK had no effect on cortical Epi and Endo cells ewensggziq (xexkqeozfe ) | Positive | 23 Oct 2018 | |||